Study directory

Mental health studies with practical context.

Public study records, presented in a clearer and more patient-friendly format for mental health research discovery.

Back to overview
23847studies shown
Showing 10,501-10,512 of 23,847
Drug study icon
TerminatedNCT05159830

Cannabidiol for Reducing Drinking in Addiction

This summary needs review. Please check the official study record and contact the research team for details.

In Bron
AddictionDrugA study involving a medication or substance.From 18 Years to 65 Years
Countries
France
Sponsor
Hôpital le Vinatier
Condition
Addiction
Drug study icon
TerminatedEUCTR 2015-000465-31

Cannabidiol for depression in bipolarity

This study was terminated in Germany. It is testing cannabidiol for depression in bipolarity.

In Germany
Bipolarity, DepressionOther
Countries
Germany
Sponsor
Charité - Universitätsmedizin Berlin
Condition
Bipolarity, Depression
Drug study icon
CompletedNCT06206291

Cannabidiol in the Treatment of Addiction

This summary needs review. Please check the official study record and contact the research team for details.

In New York
AddictionDrugFrom 18 Years to 65 Years
Countries
United States
Sponsor
Yasmin Hurd
Condition
Addiction
Drug study icon
CompletedNCT05317546

Cannabidiol in Youth Addiction

This summary needs review. Please check the official study record and contact the research team for details.

In Charleston
AddictionDrugFrom 16 Years to 22 Years
Countries
United States
Sponsor
Medical University of South Carolina
Condition
Addiction
Drug study icon
CompletedNCT05823753

Cannabidiol to Reduce Anxiety Reactivity

This summary needs review. Please check the official study record and contact the research team for details.

In San Diego
AnxietyDrugFrom 18 Years to 70 Years
Countries
United States
Sponsor
University of California, San Diego
Condition
Anxiety
Drug study icon
CompletedNCT02504151

Cannabidiol Treatment in people with Early Psychosis

This study exists to see whether a medication treatment can make care clearer and more responsive. Researchers are trying to understand whether a medication treatment can give earlier or clearer feedback during care.

Multiple locations, including New Haven
SchizophreniaDrugFrom 18 Years to 65 Years
Countries
United States
Sponsor
Yale University
Condition
Schizophrenia
Data coverage

Public registry coverage is progressing

HopeStage gathers information about mental health clinical trials from the public registries we currently index. We are progressively improving registry coverage, but this does not mean that every study in the world is already included.